Product Description
Mechanisms of Action: ERBB2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Byondis
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Trastuzumab duocarmazine](https://pryzm-maps.s3.us-west-2.amazonaws.com/9128current_maps.png)
Countries in Clinic: Belgium, Canada, Denmark, France, Italy, Korea, Netherlands, Poland, Russia, Serbia, Singapore, Spain, Sweden, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Adenocarcinoma|Endometrial Cancer|Esophageal Cancer|Gastrointestinal Cancer
Phase 1: Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2020-005575-12 | P2 |
Active, not recruiting |
Breast Cancer|Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer |
2023-06-30 |
|
SYD985.004 | P1 |
Completed |
Ovarian Cancer|Endometrial Cancer|Breast Cancer |
2023-04-24 |
27% |
BYON5667.002 | P2 |
Completed |
Breast Cancer |
2023-04-19 |
57% |
BYON5667.002 | P2 |
Completed |
Breast Cancer |
2023-04-19 |
57% |
SYD985.003 | P2 |
Completed |
Endometrial Cancer |
2023-01-26 |